| Patients with cardiac disease, such as angina, congestive heart
failure, or arrhythmia, should be closely monitored for worsening of
their clinical condition during initiation and continued treatment with
Betaseron ®.
While Betaseron ® does not have any known direct-acting
cardiac toxicity, during the post-marketing period infrequent cases
of congestive heart failure, cardiomyopathy, and cardiomyopathy with
congestive heart failure have been reported in patients without known
predisposition to these events, and without other known etiologies being
established.
Treatment with Betaseron is significantly associated
with heart palpitation. It may also be associated with hypertension
(high blood pressure), tachycardia (racing heart) and peripheral vascular
disorder.
|
